OmniAb (OABI) Research & Development (2022 - 2026)
OmniAb (OABI) posted quarterly Research & Development of $9.6 million for Q1 2026, down 23.5% year-over-year from $12.6 million in Q1 2025, and down 30.69% quarter-over-quarter from $13.9 million in Q4 2025.
OmniAb (OABI) Research & Development (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Research & Development for 5 consecutive years, with $9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 23.5% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $44.8 million (down 15.74% YoY), while the FY2025 annual figure was $47.8 million, down 13.35% from the prior year.
- Research & Development slipped to $9.6 million in Q1 2026 per OABI's latest filing, from $13.9 million in the prior quarter.
- Across five years, Research & Development topped out at $14.8 million in Q4 2023 and bottomed at $9.6 million in Q1 2026.
- Historically, Research & Development has averaged $12.8 million across 5 years, with a median of $13.3 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development advanced 27.73% — and 2026, when it declined 23.5%.
- OmniAb's Research & Development stood at $12.9 million in 2022, then grew by 14.3% to $14.8 million in 2023, then fell by 9.89% to $13.3 million in 2024, then climbed by 4.53% to $13.9 million in 2025, then sank by 30.69% to $9.6 million in 2026.
- Business Quant data shows OABI's Research & Development at $9.6 million in Q1 2026, $13.9 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 9.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.59 Mn |
| Mar 31, 2026 | 9.64 Mn |
| Dec 31, 2025 | 13.91 Mn |
| Sep 30, 2025 | 10.38 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.32 Mn |
| Jun 30, 2024 | 13.94 Mn |
| Mar 31, 2024 | 14.55 Mn |
| Dec 31, 2023 | 14.77 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 14.13 Mn |
| Mar 31, 2023 | 13.76 Mn |
| Dec 31, 2022 | 12.92 Mn |
| Sep 30, 2022 | 13.19 Mn |
| Jun 30, 2022 | 11.48 Mn |
| Mar 31, 2022 | 10.77 Mn |